



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	AA-2 Cells
<b>Catalog Number:</b>	135
<b>Lot Number:</b>	99014
<b>Release Category:</b>	D
<b>Provided:</b>	7 x 10 <sup>6</sup> cells/vial.
<b>Cell Type:</b>	AK <sup>-</sup> dCK <sup>-</sup> subclone of AA cells derived from the WIL-2 human splenic EBV <sup>+</sup> B lymphoblastoid line. WIL-2 was originally isolated from the spleen of a Caucasian male with hereditary spherocytic anemia. AA-2 cells were isolated by stepwise selection in 6-methylmercaptopyrimidine ribonuclease and arabinosylcytosine to obtain a clone with <1-3% wild type AK and dCK activity.
<b>Propagation Medium:</b>	RPMI 1640 supplemented with nonessential amino acids and 1 mM pyruvate, 90%; fetal bovine serum or horse serum, 10%.
<b>Freeze Medium:</b>	RPMI 1640, 67.5%; fetal calf serum, 10%; horse serum, 10%; DMSO, 12.5%.
<b>Growth Characteristics:</b>	Cells grow in suspension in clumps which are difficult to disperse. Stock cultures are passaged once a week with cells diluted to approximately 1 x 10 <sup>5</sup> /ml. Active cultures should be maintained between 2 x 10 <sup>5</sup> cells/ml and 8 x 10 <sup>5</sup> cells/ml. At this concentration range the cells should double every 24 hours.
<b>Morphology:</b>	Lymphoblast-like.
<b>Sterility:</b>	Negative for bacteria, fungi, and mycoplasma.
<b>Description:</b>	These cells are remarkably permissive for HIV-1 infection, extremely sensitive to virus cytopathic effects, and is useful for producing high titer virus stock.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Special Characteristics:** Expresses high levels of CD4 and binds more gp120 than other WIL-2 derivatives.

**Recommended Storage:** Liquid nitrogen.

**Contributor:** Dr. Michael Hershfield.

**References:** Chaffee S, Leeds JM, Matthews TJ, Weinhold KJ, Skinner M, Bolognesi DP, Hershfield MS. Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines. *J Exp Med* **168**:605-621, 1988.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: AA-2 from Dr. Michael Hershfield (cat# 135)." Also include the reference cited above in any publication.

**Scientists at for-profit institutions or who intend commercial use of this reagent must contact the CDC Technology Transfer Office at the following email address: [vhe6@cdc.gov](mailto:vhe6@cdc.gov) , before the reagent can be released.**

**Last Updated** September 07, 2018

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.